Cargando…
Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells
The present study investigated the terminal differentiation capacity into adipocytes and subsequent growth inhibition in A549 cancer cells treated with pioglitazone (PGZ), a PPARγ activator. The rate of cell growth in A549 cells was significantly (P < .05) inhibited in concentrations above 10 μM...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781920/ https://www.ncbi.nlm.nih.gov/pubmed/33456717 http://dx.doi.org/10.1080/19768354.2020.1847731 |
_version_ | 1783631779090923520 |
---|---|
author | Kim, Dae-Young Moon, Sun-Ha Han, Jang-Ho Kim, Mi-Jeong Oh, Seong-Ju Bharti, Dinesh Lee, Sung-Ho Park, Jong-Kuen Rho, Gyu-Jin Jeon, Byeong-Gyun |
author_facet | Kim, Dae-Young Moon, Sun-Ha Han, Jang-Ho Kim, Mi-Jeong Oh, Seong-Ju Bharti, Dinesh Lee, Sung-Ho Park, Jong-Kuen Rho, Gyu-Jin Jeon, Byeong-Gyun |
author_sort | Kim, Dae-Young |
collection | PubMed |
description | The present study investigated the terminal differentiation capacity into adipocytes and subsequent growth inhibition in A549 cancer cells treated with pioglitazone (PGZ), a PPARγ activator. The rate of cell growth in A549 cells was significantly (P < .05) inhibited in concentrations above 10 μM PGZ while maintaining less cytotoxic effects in MRC-5 fibroblasts. Following 50 μM PGZ treatment, population doubling time (PDT) was significantly (P < .05) increased by inhibition of cell growth, as per increasing PGZ exposure time by up to 4 weeks. The adiposome-like vesicles were commonly observed in the PGZ-treated A549 cells, and the vesicles were highly stained with Oil-Red O solution. In addition, the cell size and expression of GLUT4 and PPARγ were significantly (P < .05) increased, as per increasing PGZ exposure time by up to 4 weeks. The significant (P < .05) down-regulation of telomerase activity and up-regulation of senescence-associated β-galactosidase (SA β-GAL) activity was displayed in the PGZ-treated A549 cells, as per increasing PGZ exposure time by up to 4 weeks. The G1 phase of the cell cycle was also significantly (P < .05) increased in the PGZ-treated A549 cells compared with untreated A549 cells. The present results have demonstrated that activation of PPARγ using PGZ induces cellular differentiation into adipocytes and inhibits cell growth in the A549 cancer cells. The terminal differentiation into adipocytes could offer potent chemotherapy in the cancer cells showing high glucose metabolism. |
format | Online Article Text |
id | pubmed-7781920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-77819202021-01-14 Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells Kim, Dae-Young Moon, Sun-Ha Han, Jang-Ho Kim, Mi-Jeong Oh, Seong-Ju Bharti, Dinesh Lee, Sung-Ho Park, Jong-Kuen Rho, Gyu-Jin Jeon, Byeong-Gyun Anim Cells Syst (Seoul) Developmental Biology The present study investigated the terminal differentiation capacity into adipocytes and subsequent growth inhibition in A549 cancer cells treated with pioglitazone (PGZ), a PPARγ activator. The rate of cell growth in A549 cells was significantly (P < .05) inhibited in concentrations above 10 μM PGZ while maintaining less cytotoxic effects in MRC-5 fibroblasts. Following 50 μM PGZ treatment, population doubling time (PDT) was significantly (P < .05) increased by inhibition of cell growth, as per increasing PGZ exposure time by up to 4 weeks. The adiposome-like vesicles were commonly observed in the PGZ-treated A549 cells, and the vesicles were highly stained with Oil-Red O solution. In addition, the cell size and expression of GLUT4 and PPARγ were significantly (P < .05) increased, as per increasing PGZ exposure time by up to 4 weeks. The significant (P < .05) down-regulation of telomerase activity and up-regulation of senescence-associated β-galactosidase (SA β-GAL) activity was displayed in the PGZ-treated A549 cells, as per increasing PGZ exposure time by up to 4 weeks. The G1 phase of the cell cycle was also significantly (P < .05) increased in the PGZ-treated A549 cells compared with untreated A549 cells. The present results have demonstrated that activation of PPARγ using PGZ induces cellular differentiation into adipocytes and inhibits cell growth in the A549 cancer cells. The terminal differentiation into adipocytes could offer potent chemotherapy in the cancer cells showing high glucose metabolism. Taylor & Francis 2020-12-02 /pmc/articles/PMC7781920/ /pubmed/33456717 http://dx.doi.org/10.1080/19768354.2020.1847731 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Developmental Biology Kim, Dae-Young Moon, Sun-Ha Han, Jang-Ho Kim, Mi-Jeong Oh, Seong-Ju Bharti, Dinesh Lee, Sung-Ho Park, Jong-Kuen Rho, Gyu-Jin Jeon, Byeong-Gyun Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells |
title | Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells |
title_full | Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells |
title_fullStr | Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells |
title_full_unstemmed | Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells |
title_short | Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells |
title_sort | terminal differentiation into adipocyte and growth inhibition by pparγ activation in human a549 lung adenocarcinoma cells |
topic | Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781920/ https://www.ncbi.nlm.nih.gov/pubmed/33456717 http://dx.doi.org/10.1080/19768354.2020.1847731 |
work_keys_str_mv | AT kimdaeyoung terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT moonsunha terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT hanjangho terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT kimmijeong terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT ohseongju terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT bhartidinesh terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT leesungho terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT parkjongkuen terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT rhogyujin terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells AT jeonbyeonggyun terminaldifferentiationintoadipocyteandgrowthinhibitionbyppargactivationinhumana549lungadenocarcinomacells |